NCT00086502View on ClinicalTrials.gov

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Comparator: Sitagliptin

Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24

DRUG

Comparator: Placebo

Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24

DRUG

Comparator: Pioglitazone

Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8

DRUG

Metformin

"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00086502 - Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter